San Francisco, CALIFORNIA3 Active Studies

Interstitial Lung Disease Clinical Trials in San Francisco, CALIFORNIA

Find 3 actively recruiting interstitial lung disease clinical trials in San Francisco, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
888
Enrolling

Recruiting Interstitial Lung Disease Studies in San Francisco

About Interstitial Lung Disease Clinical Trials in San Francisco

Interstitial lung disease is a group of disorders characterized by progressive scarring of lung tissue, leading to breathlessness and reduced oxygen exchange. Causes include autoimmune diseases, environmental exposures, and unknown factors. Treatment includes antifibrotic medications and immunosuppressants.

There are currently 3 interstitial lung disease clinical trials recruiting participants in San Francisco, CALIFORNIA. These studies are seeking a combined 888 participants. Research is being sponsored by GlaxoSmithKline, Genentech, Inc., Cumberland Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Lung Disease Clinical Trials in San Francisco — FAQ

Are there interstitial lung disease clinical trials in San Francisco?

Yes, there are 3 interstitial lung disease clinical trials currently recruiting in San Francisco, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What interstitial lung disease treatments are being tested?

The 3 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial lung disease.

Data updated March 2, 2026 from ClinicalTrials.gov